Biomerica Announces Retirement of Chief Financial Officer (CFO), hiring of new CFO and appointment of new member to the Board of Directors - Seite 2
“Biomerica has a bold vision of developing a diagnostic guided therapy with its InFoods product. I’m honored to assume the role of Audit Committee Chairman and look forward to an exciting new fiscal year and beyond for Biomerica.” said Cathy Coste.
“It has been my pleasure and privilege to serve as Biomerica’s CFO. The Company has many talented, dedicated employees and innovative products which, I believe, will ensure the Company’s continued success.” said Janet Moore.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets
advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical
conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica primarily focus is on gastrointestinal
and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Lesen Sie auch
About InFoods
The Biomerica InFoods IBS product is designed to allow physicians to identify patient specific foods (e.g. eggs, broccoli, wheat, potatoes, corn, etc.), that when removed from the diet, may
alleviate or improve an individual's IBS symptoms including, but not limited to, constipation, diarrhea, bloating, pain and indigestion. This patented, diagnostic-guided therapy is designed to
allow for a patient-specific, guided dietary regimen to improve Irritable Bowel Syndrome (“IBS”) outcomes. The point-of-care product is being developed to allow physicians to perform the test
in-office using a finger stick blood sample while a clinical lab version of the product is expected to be the first for which the company will seek regulatory approval. A billable CPT code that can
be used by both clinical labs and physicians' offices is already available for InFoods diagnostic products. Since the InFoods product is a diagnostic-guided therapy, and not a drug, it has no drug
type side effects. An estimated 45 million people in America currently suffer from IBS making it a leading cause for patient doctor visits.